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Background: To develop patient-reported outcome instruments, statistical techniques (e.g., principal components
analysis; PCA) are used to examine correlations among items and identify interrelated item subsets (empirical factors).
However, interpretation and labelling of empirical factors is a subjective process, lacking precision or conceptual basis.
We report a novel and reproducible method for mapping between theoretical and empirical factor structures. We
illustrate the method using the pilot Aberdeen Glaucoma Questionnaire (AGQ), a new measure of glaucoma-related
disability developed using the International Classification of Functioning and Disability (ICF) as a theoretical framework
and tested in a sample representing the spectrum of glaucoma severity.
Methods: We used the ICF to code AGQ item content before mailing the AGQ to a UK sample (N = 1349) selected to
represent people with a risk factor for glaucoma and people with glaucoma across a range of severity. Reflecting
uncertainty in the theoretical framework (items with multiple ICF codes), an exploratory PCA was conducted. The
theoretical structure informed our interpretation of the empirical structure and guided the selection of theoretically-derived
factor labels. We also explored the discrimination of the AGQ across glaucoma severity groups.
Results: 656 (49%) completed questionnaires were returned. The data yielded a 7-factor solution with a simple
structure (using cut-off point of a loading of 0.5) that together accounted for 63% of variance in the scores. The
mapping process resulted in allocation of the following theoretically-derived factor labels: 1) Seeing Functions:
Participation; 2) Moving Around & Communication; 3) Emotional Functions; 4) Walking Around Obstacles; 5) Light;
6) Seeing Functions: Domestic & Social Life; 7) Mobility. Using the seven factor scores as independent variables in a
discriminant function analysis, the AGQ scores resulted in correct glaucoma severity grading of 32.5% of participants
(p < 0.001).
Conclusions: This paper addresses a methodological gap in the application of classical test theory (CTT) techniques,
such as PCA, in instrument development. Labels for empirically-derived factors are often selected intuitively whereas
they can inform existing bodies of knowledge if selected on the basis of theoretical construct labels, which are more
explicitly defined and which relate to each other in ways that are evidence based.* Correspondence: m.e.prior@abdn.ac.uk
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Measures that reflect patients’ assessment of their health
are increasingly important as outcome measures in both
clinical practice and research. The decision whether to
develop a new patient reported outcome (PRO) instru-
ment or use an existing validated measure should be
based on a thorough review of PRO instruments used in
a population of interest [1,2]. If a new instrument is re-
quired, robust and transparent methods should be used
at every stage of its development.
We have previously reported the systematic pre-
validation development of a pilot PRO – the Aberdeen
Glaucoma Questionnaire (AGQ), a new measure designed
for use in a research context to compare vision-related
disability between intervention (glaucoma screening) and
comparator (opportunistic case detection) arms at the end
of a proposed RCT [3]. The development of the AGQ
followed a systematic review of PRO instruments used in
glaucoma populations, which concluded that none of the
existing instruments was suitable for use in the proposed
RCT [2]. The pre-validation development of the AGQ
used the World Health Organisation (WHO) International
Classification of Functioning and Disability (ICF) [4] as a
theoretical framework [2,3]. This process involved using
the ICF to code the AGQ item content [3,5] by: identifying
meaningful concepts (i.e. ideas or information) contained
within each AGQ item; linking each meaningful concept
to the most precise ICF category.
Following the pre-validation development of new
instruments such as the AGQ, the next step is to con-
duct psychometric analyses of the pilot instrument in
the target population in order to assess the underlying
structure [6]. Statistical techniques from classical test the-
ory (CTT), such as principal components analysis (PCA),
continue to be widely used in the initial stages of instru-
ment testing to examine patterns of correlations among
items and identify interrelated item subsets (empirical
factors) [7,8]. Following the application of such methods,
each identified empirical factor is assigned a descriptive
label to indicate the traits it is hypothesised to measure
(e.g. near and distance vision) [7].
However, the interpretation and labelling of empirical
factors is a subjective process lacking precision or con-
ceptual basis [9]. In this paper we report a novel and
reproducible method for mapping between theoretical
and empirical factor structures. In order to illustrate the
method we present results from the early stages of test-
ing the pilot AGQ in a population representing the
spectrum of glaucoma severity, from those with a risk
factor for the disease (i.e. ocular hypertension) to those
with diagnosed glaucoma across a range of severity. The
main objectives of this paper are to report: the empirical
factors (‘content’ domains) identified within the AGQ;
explicit methods for linking the empirical factors withthe theoretical (ICF) factor structure and for assigning
theoretically informed labels. A secondary objective is to
report findings from the exploration of the discrimina-
tive ability of the AGQ across glaucoma severity.
Methods
We used a cross-sectional postal survey design to test
the pilot AGQ among patients, who had undergone
Humphrey threshold visual field testing between January
2007 and September 2009. Potential participants were
identified, by collaborating ophthalmologists, from a
visual field database of a UK Hospital based glaucoma
service (Moorfields Eye Hospital (MEH)). To be in-
cluded a patient had to have at least one visual field
entry in the database prior to the most recent and in
addition a reproducible defect as determined by the
Glaucoma Hemifield Test (a feature of the Progressor
software; Moorfields Eye Hospital/Medisoft Ltd).
The postal questionnaire included four sections: 1) the
pilot AGQ; 2) a generic health status measure - EQ-5D
[10]; 3) questions relating to baseline demographic char-
acteristics; 4) a widely used validated vision-status meas-
ure - the 25-item National Eye Institute Visual Function
Questionnaire (NEI-VFQ 25) [11], which was included
as a benchmark for comparison with the pilot AGQ.
The results presented below focus on the pilot AGQ and
on addressing the study objectives. Accordingly, we limit
our reporting of results from sections 2, 3, and 4 to sample
characteristics.
The pilot AGQ consisted of 68 items [3]. Thirty-nine
items used a 4-point response option (e.g. No = 1, Some-
times = 2, Often = 3, Always = 4). A further 8 items
contained an additional response option (e.g. unable to
perform an activity = 5). These ordinal values were then
used as real values for the PCA. Seventeen items used a
dichotomised response option (No = 1, Yes = 2), with a
further 4 items containing a third option to enable par-
ticipants to indicate uncertainty (see Additional file 1:
the AGQ). Throughout the pilot AGQ high scores indi-
cate poor outcomes (e.g. functional impairments or diffi-
culty performing activities). ‘Not applicable’ responses
were coded as missing values.
The questionnaire was mailed to 1349 patients, who
met the inclusion criteria, in March 2010 together with
an information sheet, a letter of invitation from their
MEH ophthalmologist and a reply paid envelope. One
reminder letter was sent to non-responders two weeks
later. No further contact was made with non-responders.
The return of a completed questionnaire was considered
as consent to take part. Ethics committee approval was
obtained for the study from the North of Scotland
Research Ethics Committee (Ref: 09/S0802/107). For those
returning the questionnaire, we obtained data from the
visual field databases on visual field parameters, mean
Table 2 Example of ICF coding rules applied during
pre-validation development of the pilot AGQ [16]
Example AGQ item ICF code
How much does your eyesight
interfere with your getting about
outdoors? (on the pavement or
crossing the street)
b210 seeing functions d4602 moving
around outside the home & other
buildings
Table 3 Glaucoma severity grading (better eye) of
respondents
n % Mean NEI-VFQ 25 EQ-5D
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people’s better eye is indicated to have a greater impact on
health related quality of life than does visual field loss in
the worse eye [12]. In the analyses we used the most recent
visual field data for each participant’s better eye.
Analytical strategy
Identifying the empirical factors
Any items with >5% missing data were excluded from
the analysis. The remaining missing data were not im-
puted. We conducted an exploratory PCA with Varimax
rotation using a cut-off point of 0.5 on the rotated load-
ings [13]. The use of this approach reflected the uncer-
tainty in the theoretical structure derived during the
pre-validation development. This uncertainty resulted
from the breadth of coverage of ICF components in the
pilot AGQ and within each item (cross-coding on ICF
components) [14]. The PCA identified the factors repre-
sented coherently in the data (empirical factors) to in-
form the sub-scale structure of the AGQ.
Reliability
The internal consistency of each identified factor was
assessed using Cronbach’s alpha [15]. For factors with
Cronbach’s alpha coefficients of <0.7 we explored
possible item inclusion/reduction as a strategy for
improving internal consistency [9].
Linking empirical factors with the ICF structure and label
accordingly
The ICF uses an alphanumerical system in which the
letters b, d, and e denote Body Functions (b), Activities
and Participation (d) and Environment Factors (e) [4].
These letters are followed by numeric codes that range
from one digit (to denote item content at the least spe-
cific (domain) level) to four digits (denoting highly spe-
cific attributes within each domain) (see Table 1).
Table 2 provides an example AGQ item and the ICF
coding for that item (assigned during the pre-validation
development of the pilot AGQ). In order to identify the-
oretically robust, rather than intuitive, factor labels we
mapped the a priori theoretical structure (ICF coding
for each item) to the empirical factor structure. Within
each factor, we examined the ICF code for each item and
assigned factor labels that represent the highest level of
specificity of ICF code applicable to each group of items.Table 1 Example of the ICF hierarchical alphanumeric
coding system
ICF code ICF heading for each code
d5 Self-care
d540 Dressing
d5403 Taking off footwearDiscrimination of the AGQ across glaucoma severity
We graded patients according to four levels of glaucoma
severity (ocular hypertension, mild, moderate and se-
vere) using the mean defect (MD) of the better eye [12].
The grading interval cut-offs were: MD ≥ 0 (ocular
hypertension); 0 >MD > −6 dB (mild glaucoma); -6 dB >
MD > −12 dB (moderate glaucoma); and MD ≤ −12 dB
(severe glaucoma). For an exploratory analysis we also
graded patients according to the MD in the worse eye
using the same criteria.
We conducted a breakdowns analysis using descriptive
statistics to explore the distribution of summary AGQ
scores by glaucoma severity in the better eye. In
addition, Spearman’s rho correlation coefficients were
calculated to formally represent the correlations between
each AGQ factor and glaucoma severity. Finally, we per-
formed a discriminant function analysis using leave-one-
out cross validation, in SPSS v20 for Windows, on all
seven AGQ factor scores to assess the extent to which
AGQ scores could discriminate between groups formed
on the basis of independently assessed glaucoma severity
(in the better eye) [12]. The statistical significance was
assessed using the Wilks’ lambda statistic in discrimin-
ant function analysis.
Results
Sample characteristics
Of the 1349 mailed questionnaires, 656 (49%) completed
questionnaires were returned. The mean age of responders
was 67.3 years (SD 13.3), 350 (53%) were female and 402
(61%) had mild glaucoma (0 >MD> −6 dB) based on the
severity of the visual field loss in their better eye. The
NEI-VFQ 25 and EQ5D scores by glaucoma severity are
presented in Table 3 and indicate that the scores decreaseage (yrs) Mean score
(SD)
Mean score
(SD)
Ocular
hypertension
(normal)
123 18.8 64.2 92.1 (7.50) 0.87 (0.20)
Mild 402 61.3 66.7 88.3 (11.67) 0.84 (0.20)
Moderate 82 12.5 72.1 79.1 (19.32) 0.79 (0.25)
Severe 49 7.5 72.8 68.6 (19.74) 0.80 (0.26)
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glaucoma increases.
Identifying the empirical factors
Twenty-one items in the 68 item pilot AGQ were con-
sidered unreliable (due to >5% missing data) and were
excluded from the PCA. Thirteen of these items related
to local or systemic symptoms of glaucoma. The re-
maining eight excluded items were preceded by filter
questions; the response to which determined whether
participants should answer or skip subsequent items.
Using an eigenvalue cut-off of 1 [17] the data from
the remaining 47 items yielded 7 factors that together
accounted for 61% of the variance in the scores.
Using a stringent cut-off point of a loading of 0.5 for
item inclusion [13], 30 of the 47 items loaded on to a
factor and presented a simple structure, (i.e. no items
loaded on to more than one factor). Table 4 presents the
item loadings.Reliability
Factor 7 initially contained only 2 items and the Cron-
bach’s alpha coefficient was <0.7. After examining the
other items loading onto Factor 7, which did not meet
the 0.5 cut-off, we included the next highest loading
item (Do you have difficulty with walking on uneven
ground?; item loading 0.45). The internal consistency of
the 3-item Factor 7 improved as a result. Table 5 pre-
sents the summary statistics and internal consistency co-
efficients of the 7 factors.
Items excluded after the PCA
Sixteen (of the 47) items in the PCA did not load onto
any of the seven empirical factors (using a cut-off of 0.5)
including all four items which, during the a priori theor-
etical ICF coding, were assessed to contain content that
was too general to assign specific codes (i.e. items A5,
A8, A25, A37) (see Additional file 1: the AGQ). A check
on the 16 excluded items (i.e. item loadings <0.5) also
showed that the content coverage of these items was ad-
equately represented in the 7-factor solution. For ex-
ample, the item do you have difficulty walking in dimly
lit indoor areas? was excluded from the 7-factor solu-
tion, but this item contains content covered in the items
of Factors 4, 5 and 7.Linking and labelling empirical factors with ICF structure
Table 6 presents the 31 items included in the 7-factor
solution alongside the ICF codes assigned to each of
these items during the development of the AGQ [3].
The juxtapositioning of the theoretical and empirical
factor structure facilitated the allocation of theoreticallyderived factor labels. For example, in Factor 4, the em-
pirical data suggest a label of ‘bumping and tripping',
whereas mapping back to the ICF theoretical structure
highlighted the consistency on item content associated
with ‘walking around obstacles’. In some factors, the
level of specificity of item content varied. For example in
Factor 7 all three items contain the ICF alphanumeric
code d4 (mobility), but two of the items contain highly
specific content in the d4 domain (i.e. ICF codes d410-
d429, d4502). In such cases, factor labels reflect the
highest level of specificity in common to all items, which
for Factor 7 was mobility. In other factors, the item con-
tent differed not only by specificity, but also by content
domain. In these cases, factor labels represent the com-
bination of item content. This is illustrated by Factor 6
in which the content of its four items is represented by
the label seeing functions: domestic and social life
(i.e. b210 seeing functions, d6 domestic life, d9 social
life). This mapping process resulted in the seven
theoretically-derived factor labels of: 1) Seeing Func-
tions: Participation, 2) Moving Around and Communica-
tion, 3) Emotional Function, 4) Walking Around
Obstacles, 5) Light, 6) Seeing Functions: Domestic and
Social Life, 7) Mobility.Discrimination of the AGQ across glaucoma severity
Seven composite subscale scores were computed (mean
scores) for each participant, corresponding to the seven
factors in the AGQ factor solution. Figure 1 displays the
distribution of these scores by glaucoma severity in bet-
ter eye and shows that as the severity of glaucoma
worsens, there is increasing difficulty in performing
tasks for each factor. A similar trend is displayed for the
distribution of scores by glaucoma severity in the worse
eye (Additional file 2). The Spearman’s rho correlations
between each AGQ factor and glaucoma severity (better
eye) were between 0.22 and 0.34 and all were statistically
significant (p < 0.001).
The seven factor scores were entered as independent
variables in a discriminant function analysis on severity
of glaucoma data (ocular hypertension, mild, moderate
and severe). Wilks’ Lambda indicated that the first dis-
criminant function provided most of the separation of
the groups, Chi-squared (21) = 133.89, p < 0.001. Wilks’
Lambda was non-significant for the second and third
discriminant functions (all p values >0.4). The structure
matrix (specifically, the correlations between each vari-
able and the first discriminant function) was interpreted.
This showed that the two most highly discriminating
factors were Factor 5 (Light) and Factor 4 (Walking
Around Obstacles). The profile of scores for the test of
functions 1 through 3 resulted in correct classification of
32.5% of original grouped cases.
Table 4 AGQ item loadings
N = 656
ITEM F1 F2 F3 F4 F5 F6 F7
Does your eyesight interfere with your recognising or meeting people? 0.58
Do you have difficulty watching television? (appreciating the pictures) 0.60
Do you have difficulty reading subtitles for film or TV? 0.62
Do you have difficulty reading traffic signs, street signs, or store signs? 0.52
Do you tend to confuse colours? 0.56
Do you have difficulty finding something on a crowded shelf? 0.58
How much does your eyesight interfere with using public transport
on your own? (for instance bus, train or plane)
0.59
Because of my eyesight I need help from family or friends. 0.64
Because of my eyesight I have to rely on what other people tell me. 0.53
Because of your eyesight, do you have difficulty going out of your home alone? 0.74
Do you use assistance to get around? (e.g. a guide dog, cane, companion) 0.60
Do you worry about your eyesight getting worse? 0.68
Does your eyesight make you concerned or worried about coping with everyday life? 0.62
Do you feel like a nuisance or a burden because of your eyesight? 0.61
Do you feel embarrassed because of your eyesight? 0.60
Do you feel frustrated or annoyed because of your eyesight? 0.66
Because of your eyesight do you bump against other people in crowded areas? 0.70
Do you bump into people or objects while walking? 0.72
Do you trip over objects? 0.50
Does your eyesight deteriorate in bright light? 0.67
Does your eyesight deteriorate in dim light? 0.61
Do you have difficulty with walking down steps in dim light? 0.54
Do you have difficulty adjusting from bright to dim light? (such as when
going from daylight into a dark room)
0.72
Do you have difficulty with adjusting to bright lights? 0.72
Because of my eyesight I need help from care services. 0.66
Because of your eyesight, do you have difficulty entertaining friends
and family in your home?
0.50
When pouring liquid, do you have difficulty judging the level of the liquid in
a container, such as the level of a cup of coffee?
0.55
Do you have difficulty seeing how people react to things you say? 0.61
In the last 12 months have you been anxious or worried about falling?
(This may or may not be associated with a feeling of unsteadiness)
0.65
Have you fallen in the last 12 months? 0.71
Do you have difficulty with walking on uneven ground? 0.45a
Eigenvalue 19.67 2.09 1.69 1.49 1.35 1.14 1.06
Percentage variance explained 41.8 4.4 3.6 3.2 2.9 2.4 2.3
Notes: aItem added to increase internal consistency.
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This paper addresses a methodological gap in the appli-
cation of CTT techniques, such as PCA, in instrument
development and reports a novel and reproducible
method for mapping between theoretical and empirical
factor structures to label empirically-derived factors. Weillustrate the method by presenting results from early
testing of the pilot AGQ in a population representing
the spectrum of glaucoma severity using ‘real world’
visual field data collected as part of routine care.
The exploratory PCA presented a clean 7-factor (31-item)
structure in which convergent and discriminant validity
Table 5 Summary data for the seven AGQ factors
Factor label Mean
(SD)
Median
(IQR)
Cronbach
(α)
No. of
items
1 Seeing Functions:
Participation
1.4 (0.50) 1.2 (0.50) 0.86 6
2 Moving Around and
Communication
1.2 (0.40) 1.0 (0.20) 0.85 5
3 Emotional Function 1.5 (0.51) 1.4 (0.40) 0.84 5
4 Walking Around
Obstacles
1.3 (0.46) 1.0 (0.33) 0.81 3
5 Light 1.8 (0.66) 1.6 (1.00) 0.86 5
6 Seeing Functions:
Domestic & social Life
1.1 (0.31) 1.0 (0.00) 0.78 4
7 Mobility 1.4 (0.47) 1.3 (0.67) 0.68 3
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latively high Cronbach’s alphas and simple structure
(no cross-loadings between factors). In addition, a con-
servative cut-off point of 0.5 for item inclusion was
used to alleviate concern that PCA tends to underesti-
mate the correlation when ordinal data are used. The
clean structure of the 7-factor solution suggests that the
31 items in the revised AGQ cover specific aspects of
glaucoma-related disability as opposed to general con-
tent about overall health or eyesight. Importantly, the
empirical factor structure did not reflect the response
option structure (i.e. factors contained items with differ-
ent response options). We are therefore confident that
the resultant factor structure arises from theoretical cat-
egories and not merely from ‘method variance’ [18].
Twenty-one items in the pilot 68 item AGQ were con-
sidered unreliable (due to >5% missing data) and were
excluded from the PCA. All 3 items about difficulty with
driving in different circumstances (items A55, A56, A57)
were preceded by two filter questions (i.e. A52: Have
you ever driven a car? A53: Are you currently driving at
least once in a while?). As a result, missing data for
items A55, A56 and A57 was >5% and these items were
excluded from the PCA. However, people with glaucoma
are known to experience difficulties driving in certain cir-
cumstances (e.g. at night) [19]. We therefore suggest that
because of the difficulty including ‘activity dependent
tasks’, such questions should be included alongside, but
not part of the refined 7-factor, 31-item AGQ.
This paper reports how the theoretical structure pro-
duced by the systematic ICF coding of item content [3]
was used to inform the labelling of the empirical factors.
This innovative method not only highlighted the high
level of coherence between the empirical and theoretical
structure (Table 6), it also resulted in a shift in emphasis
towards factor labels that reflect the potential impact of
glaucoma on Activities and Participation (which are key
constructs within the ICF model). For example, if look-
ing solely at the empirical data, an appropriate label forFactor 1 (Table 4) is Near and Distance Vision. However,
the theoretical structure of this factor (Table 6) teased
out the potential impact on social participation associ-
ated with impaired vision (e.g. reading, watching televi-
sion and socialising) and led to a factor label of Seeing
Functions: Participation. Thus, this explicit method of
factor labelling resulted in factor labels that have face
validity, but it also addressed the lack of precision asso-
ciated with subjective and atheoretical processes of label-
ling empirical factors. In addition, applying this method
highlights the complexity of the multi-level theoretical
structure of the items within a single empirical structure
arising from the PCA. This variation in specificity has
face validity in that it reflects the condition being inves-
tigated. In the example of the AGQ, we learn that mobil-
ity presents both general and specific challenges for
people with glaucoma (i.e. the generality of the Factor 7
label; Mobility versus the very specific label of Factor 4;
Walking Around Obstacles). For patient-reported out-
comes relating to different conditions we would expect
greater elaboration in different ICF components.
In our use of the ICF as a theoretical framework, we
are taking a nuanced view of Quality of Life (QOL) and
would expect the refined 7-factor (31-item) AGQ to be
able to distinguish associations between factor (subscale)
scores and different kinds of QOL vulnerability. How-
ever, the most appropriate scoring method and the valid-
ity of using the seven empirical factors as subscales are
questions for further research.
A secondary objective of this paper was to report find-
ings on the discriminative ability of the AGQ. In Figure 1
the boxplots indicate a clear signal in the data. For
example, visual inspection of the boxplots for the Factors
Walking Around Obstacles; Light; Mobility strongly sug-
gest that as the severity of glaucoma gets worse, there is
increasing difficulty in performing tasks. However, it must
be noted that for all 7 factors, the signal is masked by high
within-group variability. The observed trend was similar
for the boxplots illustrating the distribution of subscale
scores by glaucoma severity in the worse eye (Additional
file 2), although the signal appears weaker. The results of
the discriminant function analysis suggest that the AGQ
performs significantly better than chance in classifying re-
spondents’ glaucoma severity, and performs best discrim-
inating between those with moderate to severe glaucoma
based on the visual field loss in the better eye. However,
the use of scores for identifying individual-level severity
would not be appropriate.
The study used routine data collected in clinical care.
It was not set up to examine all patients in terms of their
clinical glaucoma severity and therefore misclassification of
cases as ocular hypertension or glaucoma could have oc-
curred. However, the use of the Glaucoma hemifield test to
filter for likely glaucoma would minimise misclassification.
Table 6 Mapping process for labelling the 7 empirical factors
Factor
no.
AGQ item content ICF codes assigned to items during
pre-validation phase (theoretical structure)
Factor label
Factor 1 Does your eyesight interfere with your recognising or
meeting people?
b210 ‘seeing’ functions, d9205 socialising.
Do you have difficulty watching television? (appreciating the pictures). d110 watching
Do you have difficulty reading subtitles for film or TV? d166 reading Seeing Functions:
Participation
Do you have difficulty reading traffic signs, street signs, or store signs? d166 reading
Do you tend to confuse colours? b21021 colour vision
Do you have difficulty finding something on a crowded shelf? b210 implicit
Factor 2 How much does your eyesight interfere with using public transport
on your own? (for instance bus, train or plane).
b210 ‘seeing’ functions, d4702 using public
motorised transportation, e540 transportation
services, systems & policies.
Because of my eyesight I need help from family or friends. b210 ‘seeing’ functions, e310, e315, e320
(physical and emotional support from immediate
family, extended family, friends). Moving Around &
Communication
Because of my eyesight I have to rely on what other people tell me. b210 ‘seeing’ functions, d310-329
communication - receiving
(non-verbal messages, written messages).
Because of your eyesight, do you have difficulty going out of
your home alone?
b210 ‘seeing’ functions, d4602 moving around
outside the home & other buildings.
Do you use assistance to get around? (e.g. a guide dog, cane, companion). d465 moving around using equipment, e115 products &
technology for personal use in daily living.
Factor 3 Do you worry about your eyesight getting worse? b152 emotional function, b210 ‘seeing’ functions
Does your eyesight make you concerned or worried about
coping with everyday life?
b152 emotional function, b210 ‘seeing’ functions
Do you feel like a nuisance or a burden because of your eyesight? b152 emotional function, b210 ‘seeing’ functions Emotional function
Do you feel embarrassed because of your eyesight? b152 emotional function, b210 ‘seeing’ functions
Do you feel frustrated or annoyed because of your eyesight? b152 emotional function, b210 ‘seeing’ functions
Factor 4 Because of your eyesight do you bump against other
people in crowded areas?
b210 seeing functions, d4503 walking around
obstacles
Walking around
obstaclesDo you bump into people or objects while walking? d4503 walking around obstacles
Do you trip over objects? d4503 walking around obstacles
Factor 5 Does your eyesight deteriorate in bright light? b21010 light sensitivity, e240 light (e.g. light
intensity, quality and colour contrasts).
Does your eyesight deteriorate in dim light? b21010 light sensitivity, e240 light.
Do you have difficulty with walking down steps in dim light? d4551 climbing (e.g. climbing steps, stairs
or kerbs), e240 light.
Light
Do you have difficulty adjusting from bright to dim light?
(such as when going from daylight into a dark room)
e240 light
Do you have difficulty with adjusting to bright lights? e240 light
Prior
et
al.BM
C
O
phthalm
ology
2013,13:72
Page
7
of
11
http://w
w
w
.biom
edcentral.com
/1471-2415/13/72
Table 6 Mapping process for labelling the 7 empirical factors (Continued)
Factor 6 Because of my eyesight I need help from care services. b210 ‘seeing’ functions, e575 general social
support services, systems & policies.
Because of your eyesight, do you have difficulty entertaining
friends and family in your home?
b210 ‘seeing’ functions, d9205 socialising.
Seeing Functions:
Domestic & Social
Life
When pouring liquid, do you have difficulty judging the level of
the liquid in a container, such as the level of a cup of coffee?
d630 household tasks.
Do you have difficulty seeing how people react to things you say? b210 ‘seeing’ functions, d3150 communication -
receiving non verbal messages (body gestures)
Factor 7 In the last 12 months have you been anxious or worried about
falling? (This may or may not be associated with a feeling of
unsteadiness).
b152 emotional function, d4 mobility (general).
MobilityHave you fallen in the last 12 months? d410-429 changing & maintaining body position.
Do you have difficulty with walking on uneven ground? d4502 walking on different surfaces.
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Factor 1: Seeing Functions: Participation Factor 2: Moving Around & Communication
Factor 3: Emotional Function Factor 4: Walking around Obstacles
Factor 5: Light Factor 6: Seeing Functions: Domestic & Social Life
Factor 7: Mobility
X axes labels: 0=ocular hypertension (MD≥0); 1=mild 
glaucoma (0>MD>-6dB); 2=moderate glaucoma (-
6dB>MD>-12dB); 3=severe glaucoma (MD≤-12dB) 
Y axis scale indicates increasing level of functional 
impairment or difficulty performing activities: 1= no 
functional impairments or difficulty performing activities 
Figure 1 Boxplots illustrating the distribution of subscale scores by glaucoma severity (in better eye).
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AGQ in a prospective study including a clinical classifica-
tion of ocular hypertension and glaucoma.
In our current analysis we evaluated visual field loss
based on MD data for each participant’s better eye (with an
additional exploratory analysis for worse eye), rather
than using a binocular visual field measure. One potential
limitation of this approach is that for individual patients,
areas of vision loss in each eye may not necessarily overlap
and visual field data for separate eyes may not capture the
person’s binocular visual field. In addition, the analysis does
not include validation of the measures, AGQ or NEIVFQ,
against location of the visual field defect as within the
design of this study we only had access to the MD a global
index of visual field loss. Location of visual field loss is
likely to relate to the severity of any patient reported
disability. This is an important area for future research.
Another limitation of the study is the potential for
response bias, given a 49% response rate. We were re-
stricted by the study ethics approval from including copies
of the questionnaires with the single reminder letter to
non-responders and from obtaining visual field data on
non-responders. Thus the effectiveness of the reminder
letter on increasing the response rate was reliant on
patients having retained the original copy of the AGQ.
The lack of visual field data on non-responders meant we
were unable to compare the demographic characteristics
and level of glaucoma severity of responders and non-
responders. Despite these limitations, the 49% response
rate is higher than generally achieved in postal surveys of
glaucoma patients [20] and to our knowledge this is the
largest study of its kind.
This paper presents a robust method for linking the
empirical factors with a theoretical factor structure and for
assigning theoretically informed labels during early testing
of new PRO instruments using CTT. We recommend
that further testing (e.g. Rasch analysis) be conducted to
provide greater insight into the psychometric properties
and dimensionality of the AGQ. Such testing will aid inter-
pretation of the AGQ as a measure of vision-related disabil-
ity in glaucoma patients and inform item refinement [21].
Conclusions
This is the first step in a series of studies that will
progressively assess the validity and utility of the AGQ.
Several glaucoma-specific PRO measures are available,
however none have linked the empirical factor structure
to the ICF model and are thus not transparent about the
constructs of health status measured [2]. In addition,
factor labels are often selected intuitively whereas they
can inform existing bodies of knowledge if selected on
the basis of theoretical construct labels, which are more
explicitly defined and which relate to each other in ways
that are evidence based. Our approach illustrates a newmethod in which decisions of what constitutes an
empirically-derived factor were driven jointly by statistical
evidence (using a higher than usual cut-off point of 0.5)
and the theoretical ICF structure established during the
pre-validation development of the AGQ.
A secondary objective of this study was to explore the
ability of the AGQ to discriminate between people without
glaucoma and those with significant disease. The data
support the validity of the AGQ in this context. Our find-
ings are based on responses from a hospital-based sample.
The AGQ is now ready for further testing in a more gen-
eral population setting including those at risk of, but not
necessarily with, established glaucoma.
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